Harmony Biosciences (NASDAQ:HRMY) Given New $42.00 Price Target at Mizuho

Harmony Biosciences (NASDAQ:HRMY) had its price objective decreased by Mizuho from $52.00 to $42.00 in a report issued on Thursday morning,Benzinga reports. Mizuho currently has an outperform rating on the stock.

HRMY has been the topic of a number of other research reports. Cantor Fitzgerald upped their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Oppenheimer restated an “outperform” rating and issued a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Wednesday. Needham & Company LLC cut their price objective on Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price for the company. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harmony Biosciences presently has an average rating of “Buy” and an average price target of $53.67.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $34.89 on Thursday. Harmony Biosciences has a 12 month low of $28.14 and a 12 month high of $41.61. The stock has a fifty day moving average price of $36.53 and a 200-day moving average price of $35.74. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.99 billion, a PE ratio of 16.54, a P/E/G ratio of 0.52 and a beta of 0.80.

Insider Activity at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 19,293 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,452 shares of company stock worth $2,831,679. 30.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Harmony Biosciences

Hedge funds have recently bought and sold shares of the business. Hillsdale Investment Management Inc. raised its stake in shares of Harmony Biosciences by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company’s stock worth $2,340,000 after buying an additional 300 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after acquiring an additional 360 shares in the last quarter. O Shaughnessy Asset Management LLC raised its position in Harmony Biosciences by 2.1% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company’s stock worth $704,000 after acquiring an additional 420 shares during the period. GAMMA Investing LLC lifted its holdings in Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after purchasing an additional 436 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock valued at $80,000 after purchasing an additional 519 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.